108 related articles for article (PubMed ID: 9598661)
1. Clinical uroselectivity: evidence from patients treated with slow release alfuzosin for symptomatic benign prostatic obstruction.
Buzelin JM; Delauche Cavallier MC; Martin D; Angel I
Br J Urol; 1998 Apr; 81(4):655-6. PubMed ID: 9598661
[No Abstract] [Full Text] [Related]
2. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
3. Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction.
Buzelin JM; Delauche-Cavallier MC; Roth S; Geffriaud-Ricouard C; Santoni JP
Br J Urol; 1997 Jun; 79(6):898-904; discussion 904-6. PubMed ID: 9202556
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Kongkanand A; Chodchoy V; Lojanapiwat B; Pumpaisanchai S; Ratana-Olarn K; Sae-Tang P; Taweemonkongsap T
J Med Assoc Thai; 2009 Jul; 92(7):969-78. PubMed ID: 19626818
[TBL] [Abstract][Full Text] [Related]
5. Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate.
Roehrborn CG
Prostate Cancer Prostatic Dis; 2006; 9(2):121-5. PubMed ID: 16304557
[TBL] [Abstract][Full Text] [Related]
6. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
7. Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin.
Saad F; Nickel JC; Valiquette L; Casey R; Kuzmarov I; Elhilali M;
Can J Urol; 2005 Aug; 12(4):2745-54. PubMed ID: 16197598
[TBL] [Abstract][Full Text] [Related]
8. Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.
Tiong HY; Tibung MJ; Macalalag M; Li MK; Consigliere D
Urol Int; 2009; 83(1):44-8. PubMed ID: 19641358
[TBL] [Abstract][Full Text] [Related]
9. Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia.
Kirby RS
Eur Urol; 1998; 33 Suppl 2():19-27. PubMed ID: 9556192
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.
Elhilali M; Emberton M; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Alcaraz A; Vallancien G;
BJU Int; 2006 Mar; 97(3):513-9. PubMed ID: 16469018
[TBL] [Abstract][Full Text] [Related]
12. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.
Rosen R; Seftel A; Roehrborn CG
Int J Impot Res; 2007; 19(5):480-5. PubMed ID: 17717526
[TBL] [Abstract][Full Text] [Related]
13. [Combined use of 5 alpha-reductase inhibitors and alpha-l adrenergic receptor blockers in patients with benign prostatic hyperplasia].
Tkachuk VN; Al'-Shukri SKh; Luk'ianov AE; Kornienko VI; Kuz'min IV
Urol Nefrol (Mosk); 1998; (3):5-8. PubMed ID: 9644979
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
Kuritzky L; Rosenberg MT; Sadovsky R
Int J Clin Pract; 2006 Mar; 60(3):351-8. PubMed ID: 16494652
[TBL] [Abstract][Full Text] [Related]
15. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
McNeill SA; Hargreave TB; Roehrborn CG;
Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
[TBL] [Abstract][Full Text] [Related]
16. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Roehrborn CG
BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
[TBL] [Abstract][Full Text] [Related]
17. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Resnick MI; Roehrborn CG
Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
[TBL] [Abstract][Full Text] [Related]
18. Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled.
McNeill SA; Daruwala PD; Mitchell ID; Shearer MG; Hargreave TB
BJU Int; 1999 Oct; 84(6):622-7. PubMed ID: 10510105
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
20. Alfuzosin: a clinically uroselective alpha1-blocker.
Höfner K; Jonas U
World J Urol; 2002 Apr; 19(6):405-12. PubMed ID: 12022709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
